Karatrasoglou EA, Chatziandreou I, Sakellariou S, et al. - Researchers tried to find out whether PD-L1 expression is associated with driver gene mutations in non-small cell lung cancer (NSCLC) individuals. The correlation between PD-L1 expression and clinicopathological parameters as well as overall survival were examined in 220 NSCLC individuals. Using 22C3 PharmDx Dako assay, PD-L1 expression was calculated by immunohistochemistry and was described as high, if TPS was ≥ 50%, low if TPS was 1%–49%, and absent, if TPS was < 1%. They detected EGFR mutations by COBAS while KRAS and BRAF mutations by pyrosequencing. Particularly for KRAS-mutated NSCLC individuals, immune checkpoint inhibitors could represent an alternative therapeutic option. Future study is needed in order to validate this observation.